HC Wainwright restated their buy rating on shares of Arvinas (NASDAQ:ARVN – Free Report) in a research report report published on Monday morning,Benzinga reports. They currently have a $81.00 price ...

In a report released today, Michael Schmidt from Guggenheim maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report), with a ...

In a report released today, Edward Tenthoff from Piper Sandler maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report), ...

Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the company, MarketBeat reports. Five ...

Arvinas is continuing its investigation of arv-102 in neurodegenerative diseases associated with lrrk2 and lysosome ...

Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ...

The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

BTIG也维持"买入"评级，目标价为69美元，对公司的现金储备和其他项目即将公布的临床数据表示乐观。相反，花旗银行将目标价从19美元下调至10美元，由于担忧该药物在某些患者群体中的疗效而维持"中性"评级。Oppenheimer将Arvinas从"跑赢大盘"降级为"持平"，反映了对该药物市场潜力的怀疑，考虑到试验结果喜忧参半。投资者正密切关注Arvinas，因为它正在应对这些发展并等待进一步的数据发 ...

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Arvinas, Inc. (ARVN) has been beaten down lately with too much selling pressure. While the stock has lost 54.9% over the past four weeks, there is light at the end of the tunnel as it is now in ...

We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the pump and dump ...